Starpharma receives $4.2M R&D tax incentive refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Adama Licenses Starpharmas Priostar for Novel 2,4-D
- Starpharma licences VivaGel BV to Aspen for ANZ
- Targeted DEP shows sustained superior performance
- VivaGel phase 3 study results
- VivaGel Demonstrates Efficacy in Bacterial Vaginosis
Later from Starpharma
- FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial
- Starpharma clinical trial programs accelerating
- Starpharma commences Dendrimer-Docetaxel clinical trial
- Starpharma completes A$18 million placement, SPP to follow
- Starpharma Interim Report and Half-year Financial Results
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma